{"entity":{"id":"dsrna-impurities","kind":"term","name":"Double-stranded RNA impurities","aka":["dsRNA impurities","double-stranded RNA contaminants"],"tldr":"RNA manufacture can also produce unwanted paired RNA material. Measuring and removing it is a product-quality question separate from the intended message.","summary":"Primary experiments identified double-stranded RNA among contaminants that affected innate immune activation and translation of in vitro-transcribed messenger RNA. Subsequent work developed and tested a cellulose-based removal method. Those studies support characterizing contaminants and their functional consequences in the tested workflows. They do not establish one universal acceptable impurity level or release method for all RNA products.\n\nOne documented origin is T7 polymerase initiating transcription from a promoter-less DNA end, producing an antisense strand and long double-stranded RNA that activated the sensor MDA5 (Mu and colleagues). In purification studies, unmodified mRNAs were translated better after HPLC purification but still induced high levels of cytokine secretion (Karikó and colleagues). A cellulose method removed at least 90 per cent of double-stranded RNA with over 65 per cent recovery regardless of mRNA length, coding sequence or nucleoside composition and increased translation in mice, and agarose gels showed that the purified mRNA stayed intact, but it removed duplexes of 30 base pairs or longer efficiently while most of a 21 base-pair duplex remained (Baiersdörfer and colleagues). Detection has its own scope: that paper notes an earlier report that about 40 base pairs of duplex are needed for detection by the J2 antibody, and a review of mRNA analytics lists immunoblot or ELISA for double-stranded RNA alongside separate integrity assays (Losada and colleagues). A lower dsRNA signal with worse fragmentation or recovery therefore does not show a better product. Method performance in those systems is not a clinical impurity limit.","asOf":"2026-11-09","links":[{"label":"Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA.","url":"https://doi.org/10.1093/nar/gkr695"},{"label":"A Facile Method for the Removal of dsRNA Contaminant from In Vitro-Transcribed mRNA.","url":"https://doi.org/10.1016/j.omtn.2019.02.018"},{"label":"An origin of the immunogenicity of in vitro transcribed RNA.","url":"https://doi.org/10.1093/nar/gky177"},{"label":"From nucleotides to intact transcripts through oligonucleotides: Integrated chromatographic strategies for therapeutic mRNA characterization.","url":"https://doi.org/10.1007/s00216-026-06615-x"}],"tags":[],"related":["in-vitro-transcription","modified-rna-nucleosides","chemistry-manufacturing-controls"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Distinguish a shorter transcript, a fold within the intended message and an unwanted complementary RNA duplex; transcript length alone cannot identify these categories. State the antibody or other detection chemistry, calibrator, sample matrix, units, detection and quantitation limits, and recovery behind a dsRNA result. Test recognised structures and relevant RNA chemistries rather than assuming every duplex is equally visible. Assess RNA size, integrity and expression separately: lower antibody signal alone cannot establish a better product or antigen-specific immunity."],"category":"Methods and models"},"route":"/terms/dsrna-impurities/","neighbours":{"term":[{"id":"chemistry-manufacturing-controls","kind":"term","name":"Chemistry, manufacturing and controls","route":"/terms/chemistry-manufacturing-controls/"},{"id":"immune-product-evidence","kind":"term","name":"Immune measurements and product evidence","route":"/terms/immune-product-evidence/"},{"id":"in-vitro-transcription","kind":"term","name":"In vitro transcription for RNA products","route":"/terms/in-vitro-transcription/"},{"id":"modified-rna-nucleosides","kind":"term","name":"Modified nucleosides in messenger RNA","route":"/terms/modified-rna-nucleosides/"}]}}